WG
AKBA icon

Winton Group’s Akebia Therapeutics AKBA Stock Holding History

Winton Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-84,484
Closed -$117K – 1155
2026
Q1 		$117K Buy
84,484
+19,301
+30% +$26.5K ﹤0.01% 1032
2025
Q4 		$105K Buy
+65,183
New +$136K ﹤0.01% 875
2020
Q1 		– Sell
-37,812
Closed -$239K – 1386
2019
Q4 		$239K Buy
+37,812
New +$180K ﹤0.01% 1414

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Winton Group's AKBA Position: Q2 2026 in Review

Winton Group sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 84,484 shares — an estimated $117K sold.

Winton Group first reported a position in AKBA in Q4 2019 and held it in 3 quarters. The position peaked at $239K in Q4 2019. 170 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Winton Group reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 84,484 Akebia Therapeutics shares in Q2 2026, an estimated $117K.
  • Winton Group first reported a position in Akebia Therapeutics in Q4 2019 and held it in 3 quarters.
  • Winton Group's Akebia Therapeutics position peaked at $239K in Q4 2019.
  • 170 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.